Full Press Release Details
IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma.
IDYA
IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma
Key Takeaway: IDEAYA Biosciences Reports End of Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single Arm Trial Design for Potential Phase 2 Registration Enabling Study in Metastatic Uveal Melanoma